Clinical trials: Recurrent Colorectal Carcinoma

Colorectal Cancer

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

• Active, not recruiting
• Age: 18 years and older
• Observational study
• Medical device

The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.

Trial name

MRD (NCT06398743)

Testing

MRD

Where

22 sites in Israel, Italy and 3 more

Volunteers

416 people

Sponsor

Exact Sciences Corporation